Staar Surgical has announced that its Visian implantable collamer lens (ICL) with CentraFLOW technology, which is driven by the KS-AquaPORT, has been approved by the Japanese Ministry of Health, Labor and Welfare.
With this approval, the range of treatment has been expanded for Visian ICL product offering to include not only the CentraFLOW technology, but also expands the treatment of myopic down to -3.0 diopters as compared to the current range which starts at -5.0 diopters.
Staar Surgical Asia Pacific region president Don Todd noted customer adoption of CentraFLOW technology driven by the KS-AquaPORT has been a key driver to our growth of Visian ICL revenues the past several quarters.
"We have just received approval in Japan, which now enables us to actively market in this important ICL market during 2014. Over 50,000 Visian ICLs with the CentraFLOW technology have been successfully implanted worldwide.
"The CentraFLOW technology approval expands the treatment range so that surgeons in Japan will be able to treat patients with myopia starting at 3.0 diopters. Dr. Shimizu’s early work on the KS-AquaPORT concept was very important to the success of this product."
The approved treatment range for the Visian ICL with CentraFLOW is -3.0 diopters to -18 diopters of myopia and the same spherical range for the Visian Toric ICL with CentraFLOW and from +1.0 diopters to +4.5 diopters of astigmatism.